Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.8652W HIGH $7.75
Volume
72.15 K
Value Traded
360.33 K
Short % Float
3.03%
-5.99%Week
-11.29%1 Month
-16.22%3 Month
-18.75%6 Month
-59.59%5 Year
-59.59%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
236.58 M
EPS (TTM)
-1.71
P/E Ratio
-
Ent. Value
150.18 M
Total Shares
62.75 M
Float Shares
32.77 M
Insiders
47.77%
Institutions
53.35%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
CAMP Catalyst Timeline
Dated clinical, regulatory and corporate events for CAMP4 Therapeutics Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for CAMP4 Therapeutics Corporation
122Total events
7Upcoming
14Tier-1 (high impact)
2024 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Trial Authorization (CTA / IND)CMP-002Ex-US Regulatory
MHRA authorizes UK sites in global Phase 1/2 trial of CMP-002
SYNGAP1-related disordersource ↗
▲IND ClearanceCMP-002IND
Regulatory clearance to initiate Phase 1/2 trial of CMP-002
SYNGAP-1 related disordersource ↗
▲Other Regulator MilestoneCMP-002Ex-US Regulatory
Received clearance from Australia's TGA and HREC to initiate Phase 1/2 trial
SYNGAP1-related disordersource ↗
▲IND ClearanceCMP-002IND
TGA and HREC clearance to initiate Phase 1/2 trial of CMP-002
SYNGAP1-related disordersource ↗
◆Trial InitiationCMP-002Trial
Initiation of Phase 1/2 clinical trial in individuals with SYNGAP1-related disorder
SYNGAP1-related disordersource ↗
●Trial InitiationSYNGAP-01Trial
Potential initiation of first-in-human Phase 1/2 clinical trial for CMP-SYNGAP-01
SYNGAP1-related disorderssource ↗
▲Trial Authorization (CTA / IND)CMP-002Ex-US Regulatory
Australia TGA and HREC clearance to initiate Phase 1/2 trial of CMP-002
SYNGAP1-related disordersource ↗
▲Ethics Committee ApprovalCMP-002Trial
Australian Human Research Ethics Committee approval for Phase 1/2 trial of CMP-002
SYNGAP1-related disordersource ↗
▲Poster PresentationCMP-002Presentation
Presentation of new preclinical data for CMP-002 at TIDES Oligonucleotide & Peptide Therapeutics conference
SYNGAP1-related disordersource ↗
●IND SubmissionCMP-002IND
Submitted first clinical trial regulatory filing for CMP-002 in Australia
SYNGAP1-related disordersource ↗
▲EU Orphan DesignationCMP-002Ex-US Regulatory
Received Orphan Designation for CMP-002 by EMA
SYNGAP1-related disordersource ↗
●Orphan Drug DesignationCMP-002Designation
Filed Orphan Drug Designation submission with FDA
SYNGAP1-related disordersource ↗
▲Partnership / LicenseCorporate
Entered into collaboration with CURE SYNGAP1 to support ProMMiS natural history study
SYNGAP1-related disordersource ↗
●PreprintPresentation
Submitted preprint of pioneering study to bioRxiv describing regRNA Capture-seq methodology
▲Runway Guidance UpdateCorporate
Cash runway expected into 2028 with $99.2 million cash as of March 31, 2026
◆Oral PresentationPresentation
Needham & Company 25th Annual Healthcare Conference Corporate Presentation
◆Trial InitiationCMP-002Trial
Expected initiation of Phase 1/2 clinical trial for CMP-002 in SYNGAP1
SYNGAP1-related disorderssource ↗
●IND SubmissionSYNGAP-01IND
Planned submission of clinical trial application for CMP-SYNGAP-01
SYNGAP1-related disorderssource ↗
◆Trial InitiationSYNGAP-01Trial
Phase 1/2 clinical trial expected to initiate as early as 2H 2026
SYNGAP1-related disorderssource ↗
●Preclinical PoCCMP-002Preclinical
GLP toxicology studies ongoing for CMP-002
SYNGAP1-related disordersource ↗
◆Oral PresentationPresentation
Corporate update at 44th Annual J.P. Morgan Healthcare Conference
▼Equity OfferingCorporate
Pricing of $30.0 million underwritten offering of common stock at $6.00 per share
▲Partnership / LicenseCorporate
Strategic collaboration with GSK to discover ASO drug candidates
neurodegenerative and kidney diseasessource ↗
▲Full ResultsCMP-001Clinical Data
Completed analysis from MAD portion of CMP-001 Phase 1 trial
Urea cycle disorderssource ↗
▲IND Enabling CompleteSYNGAP-01Preclinical
Initiation of GLP toxicology studies for CMP-SYNGAP-01
SYNGAP1-related disorderssource ↗
●IND Enabling CompleteCMP-002Preclinical
Initiated GLP toxicology studies for CMP-002
SYNGAP1-related disorderssource ↗
◆Topline ReadoutCMP-CPS-001Clinical Data
Report data from SAD and MAD cohorts of CMP-CPS-001 Phase 1 trial
urea cycle disorders (UCDs)source ↗
▼Equity OfferingCorporate
Completed private placement with $50M upfront and potential additional $50M, plus $30M underwritten offering
▲Enrollment CompleteCMP-CPS-001Trial
Completed dosing in MAD cohort 3 of CMP-CPS-001 Phase 1 trial
urea cycle disorders (UCDs)source ↗
●Preclinical PoCSYNGAP-01Preclinical
Initiate GLP toxicology studies for CMP-SYNGAP-01
SYNGAP1-related disorderssource ↗
◆Oral PresentationPresentation
Oral presentation on targeting regulatory RNAs with ASOs for SYNGAP1-Related Disorders
SYNGAP1-Related Disorderssource ↗
◆Oral PresentationCMP-CPS-001Presentation
Oral presentation of interim safety readout from Phase 1 trial of CMP-CPS-001
Urea Cycle Diseasessource ↗
◆Oral PresentationSYNGAP-01Presentation
Oral presentation of translational data for CMP-SYNGAP-01 at ASGCT 2025
SYNGAP1-related disorderssource ↗
▲Preclinical PoCSYNGAP-01Preclinical
Preclinical proof-of-concept: CMP-SYNGAP-01 restored SYNGAP1 protein levels and rescued behavioral phenotypes in mice
SYNGAP1-related disorderssource ↗
▲First Patient DosedCMP-CPS-001Trial
First patient dosed in Phase 1 trial of CMP-CPS-001
Urea Cycle Disorderssource ↗
Past FDA Catalysts and PDUFA Decisions
How CAMP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | CMP-CPS-001 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D24 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 84%
Micro Cap(rank 555 of 660)
Percentile Rank
CAMP4 Therapeutics Corporation faces pipeline headwinds (24/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CMP-CPS-001 Small moleculeNCT06247670 | OTC Deficiency | Phase 1 | ACTIVE NOT_RECRUITING | 120 | Dec 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every CAMP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CMP-001 | Urea Cycle Disorders | Phase 1 | 2025-11-06 | CMP-001 demonstrated a favorable safety profile in both the SAD and MAD portions, with no serious adverse events or discontinuations due to adverse events. Pharmacokinetic data similarly was observed to be consistent with expectations, demonstrating a dose-dependent increase in exposure (Cmax and AUC) with clear separation between groups and low-to-moderate variability in key pharmacokinetic parameters at all dose levels.Read More | CAMP4 Reports Third Quarter 2025 Financial Results and Corporate HighlightsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Gold KellyOfficer (Chief Financial Officer) | Buy | 10,000 10,000 held | $3.96 | 08/31/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CAMP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Vivo Capital, LLC | 1.7 % (6.2 %) | 18.56 M | 4.25 M |
CAMP Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CAMP ranks across every disease it competes in
Competitive Position is a premium feature
See how CAMP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCAMP News
CAMPCAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
CAMP4 Therapeutics has received authorization from the UK's MHRA to include UK sites in its Phase 1/2 clinical trial of CMP-002 for SYNGAP1-related disorder. This follows similar clearances in Australia and Argentina, with the trial expected to begin in Q4 2026. CMP-002 aims to be a first-in-class treatment addressing a significant unmet medical need.
Read more →CAMPCAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
CAMP4 Therapeutics will host a virtual Analyst Day on September 28, 2026, to discuss CMP-002, a potential therapy for SYNGAP1-related disorder. The event will feature presentations from the executive team and a leading expert, focusing on the clinical trial design for CMP-002, which aims to address significant unmet needs in this rare condition. The first-in-human Phase 1/2 trial is expected to begin in Q4 2026.
Read more →CAMPCAMP4 to Participate in Upcoming Investor Conferences
CAMP4 Therapeutics Corporation announced its participation in upcoming investor conferences. The company specializes in developing RNA-targeting therapeutics aimed at treating genetic diseases by upregulating gene expression. Webcasts of the presentations will be available on their investor relations page, with replays archived for 30 days.
Read more →CAMP▲ +20.9%on this news
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
CAMP4 has secured regulatory clearance in two jurisdictions to initiate its first-in-human Phase 1/2 clinical trial of CMP-002, targeting patients with SYNGAP-1 related disorder. The trial is expected to begin in the fourth quarter of 2026. Additionally, the company successfully raised $50.1 million from a fully subscribed second closing of private funding.
Read more →CAMPCAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
CAMP4 Therapeutics has announced the closing of the second tranche of a $100 million private placement, raising approximately $50.1 million. The funds will support the advancement of CMP-002, which has received clearance to initiate a Phase 1/2 clinical trial for SYNGAP1-related disorder. The placement involved several institutional investors and is a significant step for the company's development pipeline.
Read more →CAMP▲ +8.2%on this news
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
CAMP4 Therapeutics has secured clearance from Australia's TGA to begin a Phase 1/2 clinical trial for CMP-002, aimed at treating SYNGAP1-related disorder. This milestone allows the company to raise additional funds to support the trial and expand its clinical development. The trial represents a significant step toward offering a potential therapy for a condition currently lacking approved treatments.
Read more →CAMP▼ -10.5%on this news
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMP4 Therapeutics announced the granting of a non-qualified stock option to a new employee as part of an inducement under Nasdaq Listing Rule 5635(c)(4). The option allows the purchase of 8,000 shares at an exercise price of $4.21, vesting over four years. This move reflects the company's commitment to building its workforce while advancing its RNA-targeting therapeutic pipeline.
Read more →CAMPCAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMP4 Therapeutics announced the granting of non-qualified stock options to three new employees as an inducement for their employment. The options, totaling 39,000 shares, have a ten-year term and will vest over four years. This move is part of the company's strategy to enhance its workforce as it develops RNA-targeting therapeutics for genetic diseases.
Read more →CAMPCAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 21, 2026
CAMP4 Therapeutics has announced a non-qualified stock option grant to a new employee as an inducement for joining the company. The grant, which includes 5,000 shares, has a ten-year term and an exercise price equal to the stock's closing price on the grant date. The shares will vest over four years, contingent on the employee's continued service.
Read more →CAMPCAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
CAMP4 Therapeutics has presented new preclinical data indicating that CMP-002, its lead investigational therapeutic candidate, significantly enhances seizure threshold and reduces the severity of seizures in a mouse model of SYNGAP1-related disorder. The findings extend earlier evidence of the therapeutic potential of CMP-002, which aims to restore SYNGAP1 protein levels. The company plans to advance CMP-002 into a Phase 1/2 clinical trial in the second half of 2026, marking a critical step in developing treatments for this rare genetic disorder. This development is of significant interest to the biomedical community and could lead to new treatment options for affected individuals.
Read more →CAMP▲ +6.9%on this news
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
CAMP4 Therapeutics has reported its financial results for the first quarter of 2026, highlighting significant progress in its development of CMP-002 for SYNGAP1-related disorders. The company submitted its first regulatory filing in Australia and plans to initiate a global Phase 1/2 clinical trial in the second half of 2026. Additionally, CAMP4 received Orphan Designation from the European Medicines Agency and entered into a collaboration with CURE SYNGAP1 to support ongoing research. Despite a notable increase in net losses, the company's financial stability is supported by $99 million in cash, sufficient to fund operations into 2028.
Read more →CAMPCAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation
CAMP4 Therapeutics has submitted a preprint detailing its innovative regRNA Capture-seq methodology, which has led to the identification of a vast catalog of regulatory RNAs. This research aims to enhance gene expression through antisense oligonucleotides, with potential applications in treating genetic diseases. The company plans to advance its lead product candidate, CMP-002, into clinical trials in late 2026.
Read more →CAMPCAMP4 Appoints Michael MacLean to its Board of Directors
CAMP4 Therapeutics has appointed Michael MacLean to its Board of Directors. MacLean brings over 35 years of experience in financial leadership within the biotechnology sector. His expertise is expected to support the advancement of CAMP4's CMP-002 therapy for SYNGAP1-related disorders, which currently lacks approved treatment options.
Read more →CAMP▲ +49.4%on this news
CAMP4 to Participate in Upcoming Investor Conferences - March 6, 2026
CAMP4 Therapeutics Corporation has announced its participation in upcoming investor conferences. The company focuses on developing RNA-targeting therapeutics aimed at treating a variety of genetic diseases by upregulating gene expression. Live webcasts of the presentations will be available on their investor relations page, with replays archived for 30 days.
Read more →CAMP▲ +12.5%on this news· ran to +48% by day 3shared move
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights
CAMP4 Therapeutics Corporation has reported its financial results for the year ending December 31, 2025, announcing significant developments in its SYNGAP1 program and a collaboration with GSK. Notably, the company is set to initiate a Phase 1/2 clinical trial for its product CMP-002 in SYNGAP1 patients, with ongoing GLP toxicology studies. Despite achieving a substantial cash runway into 2028, CAMP4 experienced a notable increase in its net loss, prompting the decision to halt further investment in CMP-001. Overall, the company remains focused on advancing its RNA-targeting therapeutic candidates.
Read more →About CAMP4 Therapeutics Corporation
Headquarters100 TALCOTT AVENUE, WATERTOWN, MA, 02472
BIOPHARMAWATCH ELITE PLUS
Trade the next CAMP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime